Skip to main content

Table 2 Clinical events

From: Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study

 

CON

Group A

Group B

Group C

p value

(n = 25)

(n = 27)

(n = 26)

(n = 26)

In-hospital course

 Death, n

0

0

0

0

1.000

 MI relapse, n

0

0

0

0

1.000

 Angina pectoris attack, n

3

1

2

2

0.747

 Malignant arrhythmia, n

0

0

0

0

1.000

 Fever (body temperature >37.5 °C) lasting at least 1 week

1

2

0

1

0.589

 In-stent thrombus re-occlusion, n

     

  Drug eluting stent

0

1

0

1

0.590

  Bare stent

1

0

0

0

0.372

12 months follow-up

 Death, n

0

0

0

0

1.000

 MI relapse, n

2

1

0

1

0.574

 Angina pectoris attack, n

2

1

1

3

0.773

 Malignant arrhythmia, n

0

0

0

0

1.000

 In-stent restenosis, n

     

  Drug eluting stent

1

1

0

1

0.894

  Bare stent

1

0

1

2

0.589

 Neoplasm, n

0

0

0

0

1.000

 Revascularization, n

2

2

1

1

0.875

 Rehospitalization due to heart failure, n

4

0

2

2

0.234

 Others, n

0

0

0

0

1.000

 Combined events (death, recurrence of myocardial infarction and rehospitalization for heart failure)

6

1

2

3

0.254

  1. CON control group; group A bone marrow mononuclear cell (BMC) infusion within 1 day after percutaneous coronary intervention (PCI); group B BMC infusion at 3–7 days after PCI; group C BMC infusion at 7–30 days after PCI; MI myocardial infarct